CD19 and B-cell chronic lymphocytic leukemia: For example, in leukemia, the use of CAR T-cell therapy targeting CD19, a protein found on the surface of B cells, has led to durable responses in chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-ALL).